PMID- 33500851
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210129
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec 22
TI  - Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol.
PG  - e12217
LID - 10.7759/cureus.12217 [doi]
LID - e12217
AB  - Background and objective This study involved an investigation into the 
      pharmacokinetic and pharmacodynamic behavior of esmolol in the presence of 
      dobutamine in healthy subjects of European ancestry. Methods We conducted a 
      single-center, prospective randomized study of 16 healthy subjects with each 
      receiving an infusion of dobutamine sufficient to increase heart rate (HR) by 
      30 beats per minute (bpm) followed by a 60-minute infusion of 50 microg/kg/min 
      esmolol. Pharmacokinetics, HR, and blood pressure were evaluated for 180 minutes. 
      Results In the presence of dobutamine, esmolol elimination was substantially 
      faster than without dobutamine, Esmolol infusion reduced dobutamine-induced 
      elevation of HR reversibly whereas the dobutamine-induced systolic blood pressure 
      (SBP) reduction did not recover after the termination of the esmolol infusion. No 
      serious adverse events (AEs) were observed. Conclusions The accelerated 
      elimination of esmolol was likely due to higher cleavage through tissue esterases 
      induced by dobutamine-induced increased tissue passage cycles per time unit. The 
      HR effect was characteristic of a beta-blocker, whereas the blood pressure effect 
      was likely due to a mechanism other than direct beta-blockade. HR remained 
      elevated after the infusion of esmolol and dobutamine, most likely due to 
      persistent blood pressure reduction.
CI  - Copyright (c) 2020, Krumpl et al.
FAU - Krumpl, Gunther
AU  - Krumpl G
AD  - Pharmacology, MRN Medical Research Network, Vienna, AUT.
FAU - Ulc, Ivan
AU  - Ulc I
AD  - Pharmacology, Center for Pharmacology and Analysis (CEPHA) s.r.o, Plzen, CZE.
FAU - Trebs, Michaela
AU  - Trebs M
AD  - Operational Business Development, AOP Orphan Pharmaceuticals AG, Vienna, AUT.
FAU - Hodisch, Juri
AU  - Hodisch J
AD  - Drug Safety, AOP Orphan Pharmaceuticals AG, VIenna, AUT.
FAU - Kadlecova, Pavla
AU  - Kadlecova P
AD  - Biostatistics, Advanced Drug Development Services (ADDS) s.r.o, Brno, CZE.
FAU - Husch, Bernhard
AU  - Husch B
AD  - Research and Development, AOP Orphan Pharmaceuticals AG, Vienna, AUT.
LA  - eng
PT  - Journal Article
DEP - 20201222
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7819280
OTO - NOTNLM
OT  - cardioselective beta-blocker
OT  - dobutamine
OT  - esmolol
OT  - pharmacodynamics
OT  - pharmacokinetics
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/28 06:00
MHDA- 2021/01/28 06:01
PMCR- 2020/12/22
CRDT- 2021/01/27 05:52
PHST- 2021/01/27 05:52 [entrez]
PHST- 2021/01/28 06:00 [pubmed]
PHST- 2021/01/28 06:01 [medline]
PHST- 2020/12/22 00:00 [pmc-release]
AID - 10.7759/cureus.12217 [doi]
PST - epublish
SO  - Cureus. 2020 Dec 22;12(12):e12217. doi: 10.7759/cureus.12217.